197 related articles for article (PubMed ID: 26183300)
1. Differential association of fluconazole dose and dose/MIC ratio with mortality in patients with Candida albicans and non-albicans bloodstream infection.
Brosh-Nissimov T; Ben-Ami R
Clin Microbiol Infect; 2015 Nov; 21(11):1011-7. PubMed ID: 26183300
[TBL] [Abstract][Full Text] [Related]
2. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
3. Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre® YeastOne® for Candida albicans: a prospective observational cohort study.
van Hal SJ; Chen SC; Sorrell TC; Ellis DH; Slavin M; Marriott DM
J Antimicrob Chemother; 2014 Aug; 69(8):2210-4. PubMed ID: 24788656
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial susceptibility and clinical outcomes of Candida parapsilosis bloodstream infections in a tertiary teaching hospital in Northern Taiwan.
Lin CC; Liu CP; Hsieh FC; Lee CM; Wang WS
J Microbiol Immunol Infect; 2015 Oct; 48(5):552-8. PubMed ID: 25315213
[TBL] [Abstract][Full Text] [Related]
5. The association between fluconazole dose and MIC with mortality and persistence in candidemia.
Ghanem-Zoubi N; Qasum M; Khoury J; Zorbavel D; Arnon M; Geffen Y; Paul M
Eur J Clin Microbiol Infect Dis; 2019 Sep; 38(9):1773-1780. PubMed ID: 31197619
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for candidemia with non-albicans Candida spp. in intensive care unit patients with end-stage renal disease on chronic hemodialysis.
Serefhanoglu K; Timurkaynak F; Can F; Cagir U; Arslan H; Ozdemir FN
J Formos Med Assoc; 2012 Jun; 111(6):325-32. PubMed ID: 22748623
[TBL] [Abstract][Full Text] [Related]
7. Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance.
Fernández-Ruiz M; Guinea J; Lora-Pablos D; Zaragoza Ó; Puig-Asensio M; Almirante B; Cuenca-Estrella M; Aguado JM; ;
Clin Microbiol Infect; 2017 Sep; 23(9):672.e1-672.e11. PubMed ID: 28143788
[TBL] [Abstract][Full Text] [Related]
8. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP
Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780
[TBL] [Abstract][Full Text] [Related]
9. The emergence of non-albicans candidemia and evaluation of HiChrome Candida differential agar and VITEK2 YST® platform for differentiation of Candida bloodstream isolates in teaching hospital Kandy, Sri Lanka.
Kothalawala M; Jayaweera JAAS; Arunan S; Jayathilake A
BMC Microbiol; 2019 Jun; 19(1):136. PubMed ID: 31226938
[TBL] [Abstract][Full Text] [Related]
10. Association of fluconazole pharmacodynamics with mortality in patients with candidemia.
Baddley JW; Patel M; Bhavnani SM; Moser SA; Andes DR
Antimicrob Agents Chemother; 2008 Sep; 52(9):3022-8. PubMed ID: 18591269
[TBL] [Abstract][Full Text] [Related]
11. Candidemia in Adults at a Tertiary Hospital in China: Clinical Characteristics, Species Distribution, Resistance, and Outcomes.
Lin S; Chen R; Zhu S; Wang H; Wang L; Zou J; Yan J; Zhang X; Farmakiotis D; Tan X; Mylonakis E
Mycopathologia; 2018 Aug; 183(4):679-689. PubMed ID: 29572768
[TBL] [Abstract][Full Text] [Related]
12. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes.
Grim SA; Berger K; Teng C; Gupta S; Layden JE; Janda WM; Clark NM
J Antimicrob Chemother; 2012 Mar; 67(3):707-14. PubMed ID: 22184469
[TBL] [Abstract][Full Text] [Related]
13. Changing epidemiology of candidemia in a medical center in middle Taiwan.
Hii IM; Chang HL; Lin LC; Lee YL; Liu YM; Liu CE; Chen CH; Cheng YR; Chang CY
J Microbiol Immunol Infect; 2015 Jun; 48(3):306-15. PubMed ID: 24113067
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the clinical risk factors between Candida albicans and Candida non-albicans species for bloodstream infection.
Shigemura K; Osawa K; Jikimoto T; Yoshida H; Hayama B; Ohji G; Iwata K; Fujisawa M; Arakawa S
J Antibiot (Tokyo); 2014 Apr; 67(4):311-4. PubMed ID: 24424346
[TBL] [Abstract][Full Text] [Related]
15. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia.
Pai MP; Turpin RS; Garey KW
Antimicrob Agents Chemother; 2007 Jan; 51(1):35-9. PubMed ID: 17101684
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology, risk factors and outcomes of
Zhang W; Song X; Wu H; Zheng R
Epidemiol Infect; 2019 Sep; 147():e277. PubMed ID: 31552814
[TBL] [Abstract][Full Text] [Related]
17. The increased role of non-albicans species in candidaemia: results from a 3-year surveillance study.
Tan TY; Tan AL; Tee NW; Ng LS; Chee CW
Mycoses; 2010 Nov; 53(6):515-21. PubMed ID: 19619263
[TBL] [Abstract][Full Text] [Related]
18. Nosocomial Bloodstream Infection Due to Candida spp. in China: Species Distribution, Clinical Features, and Outcomes.
Li Y; Du M; Chen LA; Liu Y; Liang Z
Mycopathologia; 2016 Aug; 181(7-8):485-95. PubMed ID: 26994763
[TBL] [Abstract][Full Text] [Related]
19. Predictors of candidaemia caused by non-albicans Candida species: results of a population-based surveillance in Barcelona, Spain.
Rodríguez D; Almirante B; Cuenca-Estrella M; Rodríguez-Tudela JL; Mensa J; Ayats J; Sanchez F; Pahissa A;
Clin Microbiol Infect; 2010 Nov; 16(11):1676-82. PubMed ID: 20219079
[TBL] [Abstract][Full Text] [Related]
20. High-dose fluconazole therapy for cancer patients with solid tumors and candidemia: an observational, noncomparative retrospective study.
Torres HA; Kontoyiannis DP; Rolston KV
Support Care Cancer; 2004 Jul; 12(7):511-6. PubMed ID: 14986077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
